U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
'This is one of the first programs to receive platform technology designation and an important recognition by FDA of the reproducibility and adaptability of this technology across multiple therapeutic programs,' said Louise Rodino-Klapac, Ph.D., chief scientific officer and head of research & development, Sarepta. 'The designation underscores and reinforces the consistency of the data we have seen with this AAVrh74 in multiple clinical programs and is yet another example of Sarepta's continued commitment to accelerating the development of potentially transformative treatments for patients with rare genetic diseases like LGMD type 2E/R4.'
In keeping with FDA's pursuit of science-driven efficiency, the platform technology designation program is a critical tool that will help support rare disease therapies by streamlining drug development, manufacturing, and review processes for drug product applications by incorporating data from designated technologies.
To be eligible for this designation, the technology must be a well-understood and reproducible technology – such as a nucleic acid sequence, molecular structure, mechanism of action, delivery method, vector, or a combination of any such technologies – and can support the development of multiple drugs or biologics. A platform is also eligible for consideration if it is incorporated in an approved drug and preliminary evidence demonstrates that the technology has the potential to be incorporated in or utilized by more than one drug without an adverse effect on quality, manufacturing, or safety, including using the same manufacturing process. Once granted, the designation enables sponsors to leverage prior data from the platform to support investigational new drug applications (INDs), new drug applications (NDAs) or biologic license applications (BLAs).
About SRP-9003 (bidridistrogene xeboparvovec)
SRP-9003 (bidridistrogene xeboparvovec) is an investigational gene therapy designed to be systemically and robustly delivered to skeletal, diaphragm and cardiac muscle, making it an ideal candidate to treat neuromuscular diseases. SRP-9003 is intended to deliver a full-length beta-sarcoglycan transgene and uses the MHCK7 promoter, chosen for its ability to robustly express in the heart which is critically important for patients with limb-girdle muscular dystrophy Type 2E (LGMD2E), also known as beta-sarcoglycanopathy and LGMDR4, many of whom die from pulmonary or cardiac complications.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Forward-Looking Statements
This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, product candidates, the potential benefits of AAVrh74 and the potential for our therapies to be transformative for patients living with rare diseases.
Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results; success in clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or with advisory committee recommendations, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; we may not be able to comply with all FDA requests in a timely manner or at all; our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulatory decisions by, and any halts imposed by, regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
a few seconds ago
- NBC News
Dow closes 500 points lower Friday as weak jobs data and new tariffs incite sell-off
Stocks tumbled on Friday to kick off August trading as investors weighed stark signs of a weakening economy and President Donald Trump's modified tariff rates. The Dow Jones Industrial Average dropped 542.40 points, or 1.23%, closing at 43,588.58. The S&P 500 shed 1.60% to end at 6,238.01, while the Nasdaq Composite dipped 2.24% and settled at 20,650.13. The July jobs report showed nonfarm payrolls expanded by 73,000 last month, well beneath the consensus estimate from economists polled by Dow Jones that called for a 100,000 increase to payrolls. Prior months were significantly revised down. June job growth totaled just 14,000, down from 147,000. The May count came down to 19,000 from 125,000, signaling the labor market has been weakening for a while now. Bank stocks were sharply lower on fears that a slowing economy could hit loan growth. Shares of JPMorgan Chase pulled back more than 2%, while Bank of America and Wells Fargo fell more than 3% each. GE Aerospace and Caterpillar dipped nearly 1% and 2%, respectively. 'What we're seeing is concern about growth that comes at a time when market multiples have become quite elevated,' said Thierry Wizman, global FX and rates strategist at Macquarie Group. 'It's also indicative of a late summer growth scare, but you can layer that a little bit with that the idea that the doves on the FOMC ended up being correct, which lends to the idea that the Fed is late.' The numbers increased the odds that the Fed could act sooner than expected to cut rates and prop up the economy, a notion that helped stem stock losses. Traders place the likelihood of a September rate cut at roughly 86% after the jobs figures, according to CME fed futures trading. That's a reversal from Wednesday, when the odds plummeted after Fed Chair Jerome Powell signaled the central bank needs to wait and evaluate the impact of tariffs on inflation before cutting. Trump's overnight rollout of updated duties that ranged from 10% to 41% also weighed on sentiment. Goods that have been transshipped in a bid to avoid the tariffs will face another 40% levy, according to the White House. Canada, one of the U.S.'s biggest trading partners, will now have a 35% levy. That's up from 25%. 'Traders are locking in gains as tech earnings fade, macro risks grow, and seasonality turns negative. Breadth is narrowing, valuations are stretched, and defensive positioning is quietly building,' said Joseph Cusick, portfolio specialist at Calamos Investments. A sell-off in tech giants also weighed on stocks Friday. Shares of Amazon tumbled more than 8% after the e-commerce giant provided light operating income guidance for the current quarter. Apple stock slipped 2.5%. The major averages also suffered a losing week, with the S&P 500 dropping 2.4% for its worst weekly performance since May 23, and the Dow tumbling 2.9% to post its worst week since April 4. The Nasdaq lost 2.2% in the period.
Business Wire
29 minutes ago
- Business Wire
Lazard Announces Total Consideration for Lazard Group LLC's Cash Tender Offer for Its 3.625% Senior Notes Due 2027
NEW YORK--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) announced today the Total Consideration as set forth in the table below in respect of the previously announced cash tender offer (the 'Tender Offer') of its subsidiary Lazard Group LLC ('Lazard Group') for any and all of its outstanding 3.625% Senior Notes due March 1, 2027 (the 'Notes'). The Tender Offer is being made upon the terms and conditions in the Offer to Purchase dated July 28, 2025. The Tender Offer will expire today at 5:00 p.m. (New York City time), unless extended or terminated as described in the Offer to Purchase (such time and date, as they may be extended, the 'Expiration Time'). Holders of the Notes are urged to carefully read the Offer to Purchase and Notice of Guaranteed Delivery before making any decision with respect to the Tender Offer. As previously announced, in order to be eligible to receive the 'Total Consideration,' holders must (i) validly tender their Notes on or prior to the Expiration Time or (ii) deliver a properly completed Notice of Guaranteed Delivery and all other required documents at or prior to the Expiration Time and validly tender their Notes at or prior to 5:00 p.m. (New York City time) on the second business day after the Expiration Time pursuant to guaranteed delivery procedures. The Total Consideration for each $1,000 principal amount of Notes validly tendered and not validly withdrawn was determined in the manner described in the Offer to Purchase by reference to the fixed spread over the yield to maturity based on the bid side price of the UST Reference Security listed below, calculated by the Dealer Managers (as defined below) for the Tender Offer as of 2:00 p.m. (New York City time) today, the date on which the Tender Offer is currently scheduled to expire, and is set forth in the table below. In addition to the Total Consideration, accrued and unpaid interest up to, but not including, the Settlement Date (as defined below) will be payable in cash on all validly tendered and accepted Notes. Interest will cease to accrue on the Settlement Date for all Notes accepted for purchase in the Tender Offer, including any such Notes tendered through guaranteed delivery procedures. As a result, Notes tendered through the guaranteed delivery procedures will not receive accrued interest from the Settlement Date through the Guaranteed Delivery Settlement Date (as defined below), which is expected to be two business days after the Settlement Date. Payment for Notes validly tendered in the Tender Offer and accepted by Lazard Group for purchase will be made on the date referred to as the 'Settlement Date' or, in the case of Notes tendered through guaranteed delivery procedures, the 'Guaranteed Delivery Settlement Date.' The Settlement Date is expected to occur on the next business day following the Expiration Time, and the Guaranteed Delivery Settlement Date is currently expected to occur on the third business day following the Expiration Time. The closing of the Tender Offer is subject to the satisfaction or waiver of certain conditions as set forth in the Offer to Purchase. Lazard Group reserves the right, subject to applicable law, to (i) waive any and all conditions to the Tender Offer, (ii) extend the Expiration Time, (iii) amend the Tender Offer in any respect (including, without limitation, to change the fixed spread), or (iv) terminate the Tender Offer on or prior to the Expiration Time and return the Notes tendered pursuant thereto, in each case by giving written or oral notice of such extension, amendment, or termination to Global Bondholder Services Corporation, the tender agent (in such capacity, the 'Tender Agent'). This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell the Notes. The Tender Offer is being made solely by means of the Offer to Purchase and Notice of Guaranteed Delivery dated July 28, 2025. The Tender Offer is void in all jurisdictions where it is prohibited. In those jurisdictions where the securities, blue sky, or other laws require the Tender Offer to be made by a licensed broker or dealer, the Tender Offer will be deemed to be made on behalf of Lazard Group by the Dealer Managers or one or more registered brokers or dealers licensed under the laws of such jurisdictions. Citigroup Global Markets Inc. is acting as the lead dealer manager and Lazard Frères & Co. LLC is acting as co-dealer manager (together, the 'Dealer Managers') for the Tender Offer. Requests for documents may be directed to Global Bondholder Services Corporation, the information agent (in such capacity, the 'Information Agent'), by telephone at (212) 430-3774, in writing at Attn: Corporate Actions, 65 Broadway—Suite 404, New York, New York 10006 or by email at contact@ Copies of the Offer Documents are also available at the following website: Questions regarding the Tender Offer may be directed to Citigroup Global Markets Inc. by telephone at (800) 558-3745 (toll-free) or (212) 723-6106 (collect) or in writing at Attn: Liability Management Group, 388 Greenwich Street, Trading 4th Floor, New York, New York 10013. None of Lazard Group or its affiliates, their respective boards of directors, the Dealer Managers, the Tender Agent, the Information Agent or the trustee for the Notes makes any recommendation as to whether holders should tender any of their Notes. Holders must make their own decision as to whether to tender any of their Notes and, if so, the principal amount of their Notes to tender. About Lazard Founded in 1848, Lazard is one of the world's preeminent financial advisory and asset management firms, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Cautionary Note Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by the use of forward-looking terminology such as 'may,' 'might,' 'will,' 'should,' 'could,' 'would,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'target,' 'goal,' 'pipeline,' or 'continue,' and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies, business plans and initiatives and anticipated trends in our business. These forward-looking statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. These factors include, but are not limited to, those discussed in our Annual Report on Form 10-K under Item 1A 'Risk Factors,' and also discussed from time to time in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including the following: Adverse general economic conditions or adverse conditions in global or regional financial markets; Changes in international trade policies and practices, including the implementation of tariffs, proposed further tariffs, and responses from other jurisdictions, and the economic impacts, volatility and uncertainty resulting therefrom; A decline in our revenues, for example due to a decline in overall mergers and acquisitions ('M&A') activity, our share of the M&A market or our assets under management ('AUM'); Losses caused by financial or other problems experienced by third parties; Losses due to unidentified or unanticipated risks; A lack of liquidity, i.e., ready access to funds, for use in our businesses; Competitive pressure on our businesses and on our ability to retain and attract employees at current compensation levels; and Changes in relevant tax laws, regulations or treaties or an adverse interpretation of those items. These risks and uncertainties are not exhaustive. Our SEC reports describe additional factors that could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties, nor can management assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. As a result, there can be no assurance that the forward-looking statements included in this release will prove to be accurate or correct. Although we believe the statements reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, achievements or events. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this release to conform our prior statements to actual results or revised expectations and we do not intend to do so. Lazard, Inc. is committed to providing timely and accurate information to the investing public, consistent with our legal and regulatory obligations. To that end, Lazard and its operating companies use their websites, and other social media sites to convey information about their businesses, including the anticipated release of quarterly financial results, quarterly financial, statistical and business-related information, and the posting of updates of AUM in various mutual funds, hedge funds and other investment products managed by Lazard Asset Management LLC and Lazard Frères Gestion SAS.
Yahoo
33 minutes ago
- Yahoo
Down 90% From Its High, Is There Still Hope for Opendoor Stock?
Key Points Opendoor's stock plummeted as interest rates rose. But it could stabilize as interest rates decline and the housing market heats up. Its stock soared over the past month, but it still looks undervalued. 10 stocks we like better than Opendoor Technologies › Opendoor Technologies (NASDAQ: OPEN), the leading instant buyer of homes in America, went public on Dec. 21, 2020, by merging with a special purpose acquisition company (SPAC). Its stock opened at $31.47 on its first day, and it eventually closed at a record high of $35.88 on Feb. 11, 2021. But today, the stock trades at about $2.50 a share. It plummeted more than 90% as rising interest rates and other macro headwinds chilled the housing market. Let's see if this out-of-favor real estate stock might bounce back as interest rates decline. The last major iBuyer standing As an instant buyer (or iBuyer), Opendoor uses its AI algorithms to make instant cash offers for homes. It fixes up those properties and relists them on its own marketplace. That streamlined business model flourished when interest rates were low and the housing market was hot. However, the Fed's rate hikes in 2022 and 2023 ended the post-pandemic housing boom while driving up the costs of buying and renovating those properties. That's why Zillow and Rocket's Redfin both shut down their integrated iBuying platforms in 2022. But with Zillow and Redfin out of the picture, Opendoor is the one big major iBuyer standing. It's expected to generate more than six times as much revenue as its closest competitor, Offerpad, this year. So if interest rates decline, the housing market warms up, and economies of scale kick in, its growth could accelerate again. When will Opendoor reach an inflection point? In 2021, Opendoor's revenue and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) skyrocketed as the pandemic eased and sales of new homes surged. Unfortunately, rising rates forced it to reduce its home purchases in 2022 and 2023. Its adjusted EBITDA margins turned red again, and it racked up more losses. Metric 2021 2022 2023 2024 Revenue $8 billion $15.6 billion $6.9 billion $5.2 billion Revenue growth 211% 94% (55%) (26%) Homes bought 36,908 34,962 11,246 14,684 Adjusted EBITDA margin 0.7% (1.1%) (9%) (2.8%) Net loss ($662 million) ($1.4 billion) ($275 million) ($392 million) Data source: Opendoor. But in 2024, Opendoor bought more homes again as the Fed's three interest rate cuts stabilized the housing market. Its adjusted EBITDA margin also improved as it pruned its workforce, reduced its resale transaction costs and commissions, and streamlined its other spending. In the first quarter of 2025, its revenue only dipped 2% year over year to $1.2 billion, and its home purchases rose 4% to 3,609 units. Its adjusted EBITDA margin also improved 160 basis points to negative 2.6% as it narrowed its net loss from $109 million to $85 million. For the second quarter, it expects its revenue to decline less than 1% at the midpoint with a positive adjusted EBITDA margin of about 1%. For the full year, analysts expect its revenue to decline about 5% to $4.9 billion with an adjusted EBITDA margin of negative 0.7%. That stabilization indicates the storm clouds are finally dissipating. Does Opendoor look undervalued relative to its growth potential? Four catalysts could turn that stabilization into an acceleration. First, the Fed is expected to reduce its rates at least two more times this year. That could drive more sellers and buyers back to the housing market. Second, it's partnering with more homebuilders and real estate platforms (including Zillow and Redfin) to reach more sellers. Third, the company has been upgrading its own AI algorithms to improve the accuracy and speed of its home valuations and repair estimates. Lastly, it's expanding Opendoor Exclusives, its new marketplace, which directly matches buyers to sellers with its AI pricing engine. That capital-light approach, which doesn't require Opendoor to buy and renovate any houses on its own, would help it generate higher-margin commissions without increasing its debt. For 2026, analysts expect revenue to rise 18% to $5.8 billion as its adjusted EBITDA margin rises to nearly break-even levels. With an enterprise value of $3.06 billion, it still looks undervalued at a multiple of less than 1 next year's sales. Opendoor's stock already surged about 370% over the past month. A new meme stock rally, viral comments from a hedge fund manager about it becoming the "next Carvana," and speculation of a reverse stock split brought back the bulls. But if you expect its growth to accelerate again, it isn't too late to buy its volatile stock. Should you buy stock in Opendoor Technologies right now? Before you buy stock in Opendoor Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Opendoor Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $630,291!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,791!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Zillow Group. The Motley Fool recommends Rocket Companies. The Motley Fool has a disclosure policy. Down 90% From Its High, Is There Still Hope for Opendoor Stock? was originally published by The Motley Fool Sign in to access your portfolio
